Evicenter
P&T meetings

Zipalertinib (CLN-081)

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417
Manufacturer
Taiho Oncology
Regulatory submission
NDA submitted February 2026
Launch
Not announced
Last updated
75 sources

Product information and disease descriptionPlace of product in therapyDisease description

Burden of EGFR exon 20 insertion-mutated non-small-cell lung cancer

3 evidence topics · 6 sources

Economic impact of EGFR exon 20 insertion-mutated non-small-cell lung cancer on families

Not applicable.

Economic impact of diagnostic testing

No evidence found.